SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced the publication of data in the May issue of Immunity regarding antibodies with significant potency and breadth against human immunodeficiency virus (HIV). The study, titled “Broadly neutralizing HIV antibodies define a novel glycan-dependent epitope on the pre-fusion conformation of gp41 on cleaved envelope trimers,” describes a set of recently isolated human monoclonal antibodies that target a region of HIV that differs from the epitopes recognized by broadly neutralizing antibodies (bNAbs) discovered previously.
Help employers find you! Check out all the jobs and post your resume.
